Hims & Hers Health, Inc. (HIMS) Stock Forecast Oct. 14, 2026
Analysis updated on Oct. 14, 2026 (UTC) · Alpha · vs marketSwitch to Total · NYSE
Hims & Hers Health, Inc. (HIMS) stock forecast summary
On Oct. 14, 2026, HIMS is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 5379 stocks scored that day.
Its market capitalization is not available, so no size classification is given.
A per-ticker accuracy statistic for HIMS is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.3%, buy ≥ +0.5%, sell < -0.5%, strong sell < -1.6% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-13 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, HIMS included.
Follow HIMS freeHIMS price chart and AI forecast
How HIMS ranks among 5379 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Hims & Hers Health, Inc. (HIMS) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Services-Offices & Clinics of Doctors of Medicine peers listed below that report each metric.
Valuation & Market
| Metric | HIMS | Rank |
|---|---|---|
| EPS | $-0.03 | – |
Profitability & Margins
| Metric | HIMS | Rank |
|---|---|---|
| ROE | -43.8% | 5/6 |
| ROA | -3.9% | 4/8 |
| ROIC | -7.2% | 3/8 |
| Gross Margin | 68.4% | 4/6 |
| Operating Margin | -6.0% | 4/8 |
| Net Margin | -5.5% | 4/8 |
| EBT Margin | -6.3% | 3/8 |
| Tax Rate | 13.2% | – |
Financial Health
| Metric | HIMS | Rank |
|---|---|---|
| Current Ratio | 0.93x | 3/8 |
| Quick Ratio | 0.87x | 3/6 |
| D/E Ratio | 10.20x | 2/6 |
| Financial Leverage | 11.20x | 2/6 |
| Interest Coverage | -141.9x | 8/8 |
| Working Capital | -$99M | 7/8 |
Cash Flow
| Metric | HIMS | Rank |
|---|---|---|
| Operating Cash Flow | $263M | 1/8 |
| Free Cash Flow | $62M | 3/6 |
| Capital Spending | -$202M | 6/6 |
| OCF Growth YoY | 0.7% | 2/5 |
| FCF/Sales | 2.4% | 4/6 |
| CapEx/Sales | 7.8% | 1/6 |
Operational Efficiency
| Metric | HIMS | Rank |
|---|---|---|
| Asset Turnover | 0.71x | 6/7 |
| Receivables Turnover | 6.9x | – |
| Inventory Turnover | 9.3x | – |
| Days Sales Outstanding | 53 days | – |
| Days Inventory | 39 days | – |
| Payables Period | 225 days | 2/5 |
| Cash Conversion Cycle | -132 days | – |
Income Statement
| Metric | HIMS | Rank |
|---|---|---|
| Total Revenue | $2.58B | 1/7 |
| Operating Income | -$154M | 7/8 |
| Net Income | -$142M | 7/8 |
| Cost of Goods Sold | $814M | 1/6 |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $1.38B | |
| Cash & Short-term Investments | $610M | |
| Accounts Receivable | $375M | |
| Inventory | $88M | |
| Total Liabilities | $3.30B | |
| Short-term Debt | $982M |
HIMS quarterly financials and insider trading
Hims & Hers Health, Inc. (HIMS) industry peers
Companies classified under the same SEC industry code as Hims & Hers Health, Inc. (Services-Offices & Clinics of Doctors of Medicine): 8 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| HIMS Hims & Hers Health, Inc. | ▶ | N/A |
| TDOC Teladoc Health, Inc. | ▶ | $1.09B |
| SBC Sbc Medical Group Holdings Inc | ▼ | $554M |
| LFMD Lifemd, Inc. | ▲ | $119M |
| AIRS Airsculpt Technologies, Inc. | ▲ | $117M |
| HLYK Healthlynked Corp | ▲ | $7M |
| CDIX Cardiff Lexington Corp | ▼ | N/A |
| STLN Starling Oncology, Inc. | ▲ | N/A |
Where HIMS sits on the market map
Hims & Hers Health, Inc. (HIMS) stock news
Loading...
Hims & Hers Health, Inc. (HIMS) stock forecast FAQ
What is the Hims & Hers Health, Inc. (HIMS) stock forecast?
On Oct. 14, 2026, HIMS is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 5379 stocks scored that day.
How accurate are Hims & Hers Health, Inc. stock predictions?
A per-ticker accuracy statistic for HIMS is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Hims & Hers Health, Inc. forecasts updated?
Hims & Hers Health, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 14, 2026.
Which companies are Hims & Hers Health, Inc.'s industry peers?
8 issuers in our coverage, HIMS included, share the SEC industry code Services-Offices & Clinics of Doctors of Medicine. The largest are: Teladoc Health, Inc. (TDOC), Sbc Medical Group Holdings Inc (SBC), Lifemd, Inc. (LFMD), Airsculpt Technologies, Inc. (AIRS), Healthlynked Corp (HLYK), Cardiff Lexington Corp (CDIX).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.